WALTHAM, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced that it will present at the following investor conferences:
Morgan Stanley 22nd Annual Global Healthcare Conference
Fireside Chat Date: Friday, September 6, 2024
Fireside Chat Time: 10:00 AM ET
Location: New York, NY
H.C. Wainwright 26th Annual Global Investment Conference
Fireside Chat Date: Monday, September 9, 2024
Fireside Chat Time: 9:30 AM ET
Location: New York, NY
2024 Cantor Global Healthcare Conference
Fireside Chat Date: Wednesday, September 18, 2024
Fireside Chat Time: 10:55 AM ET
Location: New York, NY
Live webcasts of the fireside chats will be available in the investor section of the company’s website at investors.invivyd.com and will be archived for approximately 90 days following the events.
About Invivyd
Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2. The company’s proprietary INVYMAB™ platform approach combines state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering. INVYMAB is designed to facilitate the rapid, serial generation of new monoclonal antibodies (mAbs) to address evolving viral threats. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit https://invivyd.com/ to learn more.
Contacts:
Media Relations
(781) 208-0160
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations
(781) 208-0160
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.76 |
Daily Change: | -0.04 -4.48 |
Daily Volume: | 562,886 |
Market Cap: | US$90.190M |
November 14, 2024 October 29, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB